Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0065-2571(73)90005-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mechanisms of Regulation of Cell Fate in Breast Development and Cancer.
Adv Exp Med Biol
January 2025
Laboratory of Stem Cells and Cancer (LSCC), Université Libre de Bruxelles (ULB), Brussels, Belgium.
This chapter focuses on the mechanisms of regulation of cell fate in breast development, occurring mainly after birth, as well as in breast cancer. First, we will review how the microenvironment of the breast, as well as external cues, plays a crucial role in mammary gland cell specification and will describe how it has been shown to reprogram non-mammary cells into mammary epithelial cells. Then we will focus on the transcription factors and master regulators which have been established to be determinant for basal (BC) and luminal cell (LC) identity, and will describe the experiments of ectopic expression or loss of function of these transcription factors which demonstrated that they were crucial for cell fate.
View Article and Find Full Text PDFOmics-based Identification of the Broader Effects of 2-hydroxyisoflavanone Synthase Gene Editing on a Gene Regulatory Network Beyond Isoflavonoid Loss in Soybean Hairy Roots.
Plant Cell Physiol
December 2024
RIKEN Center for Sustainable Resource Science, Yokohama 230-0045, Japan.
Soybean (Glycine max) is a leguminous crop cultivated worldwide that accumulates high levels of isoflavones. Although previous research has often focused on increasing the soybean isoflavone content because of the estrogen-like activity of dietary soy in humans, the rapidly increasing demand for soybean as a plant-based meat substitute has raised concerns about excessive isoflavone intake. Therefore, the production of isoflavone-free soybean has been anticipated.
View Article and Find Full Text PDFIdentification and validation of Novel Estrogen Biosynthesis Biomarkers in Sinonasal Inverted Papilloma.
Int J Med Sci
January 2025
Department of Otolaryngology, Head and Neck Surgery, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan.
Article Synopsis
- Sinonasal inverted papilloma (SNIP) has a high recurrence rate and the potential to become malignant, but its specific metabolic pathways and biomarkers are not fully understood.
- RNA sequencing identified significant gene alterations related to the estrogen biosynthesis pathway and highlighted five key biomarkers (AKR1B10, CYP1B1, CYP2C19, CYP3A5, and HSD17B13) that were correlated with SNIP pathogenesis.
- Functional analysis indicated that these biomarkers are involved in epithelial cell proliferation and EGFR signaling regulation, suggesting their potential as diagnostic and therapeutic targets for managing SNIP.
The role of lignin in 17β-estradiol biodegradation: insights from cellular characteristics and lipidomics.
Microb Cell Fact
December 2024
College of Veterinary Medicine, Jilin Agricultural University, Changchun, 130118, China.
17β-estradiol (E2) is an endocrine disruptor, and even trace concentrations (ng/L) of environmental estrogen can interfere with the endocrine system of organisms. Lignin holds promise in enhancing the microbial degradation E2. However, the mechanisms by which lignin facilitates this process remain unclear, which is crucial for understanding complex environmental biodegradation in nature.
View Article and Find Full Text PDFNeratinib enhances the efficacy of CDK4/6 inhibitor plus endocrine therapy in HR/HER2-low breast cancer cell line ZR-75-1 via hsa-miR-23a-5p.
Sci Rep
December 2024
Chinese Medicine Guangdong Laboratory, Hengqin, 519031, Guangdong, China.
HR/HER2-low breast cancer is a significant subgroup of conventional HR/HER2-negative breast cancer, and combination of CDK4/6 inhibitor and endocrine therapy is the standard first-line and second-line treatments for advanced HR/HER2-low breast cancer. Nevertheless, it remains uncertain whether HER2 signaling affects the effectiveness of CDK4/6 inhibitor administered in combination with endocrine therapy for HR/HER2-low breast cancer and suitable intervention measures. This study revealed poor efficacy for CDK4/6 inhibitor combined with endocrine therapy for HR/HER2-low breast cancer in vitro and in vivo models.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!